• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Epidemiol Glob Health . Epidemiological Characteristics of MERS-CoV Human Cases, 2012- 2025

tetano

Editor, Senior Moderator
J Epidemiol Glob Health


. 2025 Aug 6;15(1):103.
doi: 10.1007/s44197-025-00446-2. Epidemiological Characteristics of MERS-CoV Human Cases, 2012- 2025

Mazin Barry[SUP] 1 2 [/SUP]



Affiliations
Free article Abstract

Aim: To describe the epidemiological characteristics of Middle East respiratory syndrome coronavirus (MERS-CoV) human cases since the first reported case in 2012.
Methods: This is a retrospective descriptive epidemiological analysis of all laboratory-confirmed MERS-CoV human cases reported to the World Health Organization (WHO) from 2012 to May 2025. Cumulative cases globally, along with their demographics, comorbidities, epidemiological exposure, symptoms, hospital admissions, and mortality, were included. Descriptive analysis was used for the data.
Results: Between March 2012 and May 2025, a total of 2,626 laboratory-confirmed MERS-CoV human cases were reported to the WHO, with 947 (36.1%) resulting in deaths. The majority of cases occurred in the Kingdom of Saudi Arabia (KSA), with 2,217 (84.4%) human cases and 866 (39.1%) deaths. Twenty-six other countries reported human cases, with the highest number occurring in South Korea, which reported 186 cases (7.1%). The highest number of cases occurred in 2014, with 662 (29.9%) cases, followed by 2015, with 453 (20.4%) cases. Almost half of the cases in KSA (44.7%) were secondary infections, and most (83%) required hospital admission, with 39.7% requiring admission to intensive care unit. The most common comorbidities were diabetes mellitus, chronic heart disease, and chronic renal failure. Between 2020 and the end of May 2025, 113 new human cases of MERS-CoV infection (4.3%) were reported, with the majority occurring in KSA. In 2025 alone, 10 new cases were reported, with two deaths. Secondary transmission occurred in 60% of these cases. Seven of the 10 cases were reported in April 2025 alone.
Conclusion: Between 2012 and May 2025, the majority of MERS-CoV infections occurred in the Kingdom of Saudi Arabia and had a high mortality, reaching 40%. Although most cases were reported between 2014 and 2015, new human cases are still ongoing and are increasing in 2025. Continued epidemiological investigation and surveillance are needed.

Keywords: 2012–2025; Epidemiology; Kingdom of Saudi Arabia; MERS-CoV; Middle East respiratory syndrome coronavirus.

 
Back
Top